| NCT03761030 | New York State Psychiatric Institute|National Institute of Mental Health (NIMH) | Major Depressive Disorder|Dysthymia|Depression | 2019-01-09 | PHASE4 |
| NCT01283594 | Biotie Therapies Inc. | Parkinson´s Disease | 2011-03 | PHASE2|PHASE3 |
| NCT02347059 | University of Toronto|Michael J. Fox Foundation for Parkinson´s Research | Parkinson´s Disease | 2015-01 | PHASE2 |
| NCT04357483 | Asan Medical Center | Pancreatic Tumor | 2018-02-01 | PHASE4 |
| NCT03959540 | Bial - Portela C S.A. | Parkinson Disease | 2020-04-28 | |
| NCT07370532 | Ihab Elsayed Hassan | Parkinson Disease | 2026-01-30 | PHASE2 |
| NCT01437293 | New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA)|Columbia University | Cocaine Abuse | 2010-08 | PHASE1 |
| NCT03891095 | Beijing Normal University|Yale University | Oxytocin Group|L-DOPA Group|Placebo Group | 2018-12-01 | NA |
| NCT04469959 | Vanderbilt University Medical Center|Emory University|University of Pittsburgh|University of Pittsburgh Medical Center|Rutgers University|University of North Carolina, Chapel Hill | Late Life Depression|Cognitive Decline|Depressive Disorder, Treatment-Resistant|Levodopa|Gait Impairment | 2021-02-15 | PHASE2 |
| NCT00439049 | The University of Texas Health Science Center, Houston|National Institute on Drug Abuse (NIDA) | Cocaine Abuse|Cocaine Dependence|Opiate Dependence|Alcohol Dependence|Substance Abuse | 2005-10 | |
| NCT04244058 | Weill Medical College of Cornell University | Disorder of Consciousness|Traumatic Brain Injury | 2020-09-23 | EARLY_PHASE1 |
| NCT01646255 | UCB Pharma|UCB Trading (Shanghai) Co. Ltd. | Idiopathic Parkinson´s Disease | 2012-07 | PHASE3 |
| NCT03754062 | King´s College London|Medical Research Council | Haloperidol|Placebo|L-DOPA | 2017-06-01 | PHASE1 |
| NCT01092065 | Novartis | Parkinson´s Disease | 2010-03 | PHASE2 |
| NCT04558112 | University of Wisconsin, Madison|National Institute of Mental Health (NIMH) | PTSD|Post Traumatic Stress Disorder | 2021-02-18 | PHASE2 |
| NCT00406029 | Merck Sharp & Dohme LLC | Parkinson Disease|Movement Disorders|Central Nervous System Diseases|Neurodegenerative Diseases|Brain Diseases | 2006-11-20 | PHASE2 |
| NCT03243552 | University of California, Los Angeles|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | ASD | 2017-06-01 | PHASE2 |
| NCT00537017 | Merck Sharp & Dohme LLC | Parkinson Disease|Neurodegenerative Diseases|Central Nervous System Diseases|Movement Disorders|Brain Diseases | 2007-11-23 | PHASE2 |
| NCT02578849 | Aarhus University Hospital|University of Copenhagen | Parkinson?s Disease | 2012-01 | |
| NCT01770145 | MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals | Parkinson´s Disease|Motor Symptoms|Akinesia|Hypomobility|Delayed Levodopa Onset | 2012-12 | PHASE4 |
| NCT02769793 | Seoul National University Hospital|SMG-SNU Boramae Medical Center|Samsung Medical Center | Parkinson Disease | 2015-06 | PHASE4 |
| NCT02116465 | Desitin Arzneimittel GmbH | Fasted State | 2014-03 | PHASE1 |
| NCT04952194 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Parkinson Disease | 2022-01-01 | PHASE4 |
| NCT05901350 | Qilu Hospital of Shandong University | Parkinson Disease|Visual Impairment | 2019-06-01 | NA |
| NCT03140956 | Orion Corporation, Orion Pharma | Parkinson Disease | 2017-04-19 | PHASE1 |
| NCT00096720 | Institute for Neurodegenerative Disorders|Boehringer Ingelheim|United States Department of Defense | Parkinson Disease|Parkinsonian Syndrome | 2004-02 | PHASE2 |
| NCT00693862 | Orion Corporation, Orion Pharma | Pharmacokinetics | 2006-12 | PHASE1 |
| NCT01568073 | Bial - Portela C S.A. | Parkinson´s Disease | 2011-03 | PHASE3 |
| NCT05250141 | Laboratorios Andromaco S.A. | Bioequivalence | 2022-02-14 | PHASE1 |
| NCT01883505 | NeuroDerm Ltd. | Parkinson´s Disease | 2014-01-06 | PHASE2 |
| NCT00143026 | Novartis | Parkinson´s Disease | 2005-07 | PHASE4 |
| NCT00625547 | Pfizer | Restless Legs Syndrome | 2003-01 | PHASE3 |
| NCT04513340 | Hong Kong WD Pharmaceutical Co., Limited | Parkinson Disease | 2020-08-13 | PHASE1 |
| NCT00006337 | National Institute of Neurological Disorders and Stroke (NINDS) | Parkinson´s Disease | 2000-10 | PHASE2 |
| NCT01026428 | Newron Pharmaceuticals SPA | Idiopathic Parkinson´s Disease | 2009-09 | PHASE1|PHASE2 |
| NCT00272688 | University Hospital, Akershus|Solvay Pharmaceuticals | Parkinson Disease | 2006-01 | PHASE4 |
| NCT00102284 | University Hospital Muenster | Healthy | 2004-03 | PHASE4 |
| NCT02764125 | Orion Corporation, Orion Pharma | Parkinson´s Disease | 2016-04-08 | PHASE2 |
| NCT07444892 | Emory University|Morningside Center for Innovative and Affordable Medicine | Diabetic Retinopathy | 2022-04-18 | PHASE2 |
| NCT01281475 | Wen-Hann Tan|Rady Children´s Hospital, San Diego|University of California, San Francisco|Baylor College of Medicine|Vanderbilt University Medical Center|Greenwood Genetic Center|Children´s Hospital Medical Center, Cincinnati|Angelman Syndrome Foundation, Inc. | Angelman Syndrome | 2011-01 | PHASE2|PHASE3 |
| NCT06225869 | University Hospital, Geneva | Parkinson Disease | 2023-04-19 | |
| NCT02073773 | Singapore General Hospital|Singapore University of Technology and Design | Ischaemic Stroke | 2014-01 | PHASE3 |
| NCT01545856 | GlaxoSmithKline | Cardiovascular Event|Parkinson Disease | 2011-09 | |
| NCT03235037 | Bennett Lavenstein | Angelman Syndrome | 2013-11-26 | NA |
| NCT06075771 | Emory University|National Institute of Mental Health (NIMH) | Anhedonia|Depression | 2023-11-21 | PHASE4 |
| NCT00013624 | National Institute of Neurological Disorders and Stroke (NINDS) | Parkinson´s Disease | 2001-03 | PHASE2 |
| NCT02312232 | Orion Corporation, Orion Pharma | Parkinson´s Disease | 2014-11 | PHASE1 |
| NCT00004733 | National Institute of Neurological Disorders and Stroke (NINDS) | Parkinson´s Disease | 1998-01 | PHASE3 |
| NCT04723147 | Emory University|National Institute of Mental Health (NIMH) | Depression|Anhedonia | 2021-01-29 | PHASE4 |
| NCT00357994 | AbbVie (prior sponsor, Abbott)|Quintiles, Inc. | Advanced Parkinson´s Disease | 2009-01 | PHASE3 |
| NCT02778594 | Bial - Portela C S.A. | Parkinson´s Disease (PD) | 2005-09 | PHASE1 |
| NCT00111371 | University Hospital Muenster | Dyslexia | 2005-01 | PHASE4 |
| NCT02785978 | Institut de Myologie, France | Parkinson Disease|Healthy Volunteers | 2016-06 | NA |
| NCT00144209 | Boehringer Ingelheim | Restless Legs Syndrome | 2003-02 | PHASE3 |
| NCT06234995 | Emory University|National Institute of Neurological Disorders and Stroke (NINDS) | Parkinson Disease | 2021-08-09 | PHASE4 |
| NCT04742348 | University of Washington | Alcohol Drinking | 2023-02 | PHASE4 |
| NCT00713583 | The University of Texas Health Science Center, Houston|National Institute on Drug Abuse (NIDA) | Cocaine Dependence | 2008-01 | PHASE2 |
| NCT00914134 | University of Helsinki|Solvay Pharmaceuticals | Parkinson´s Disease | 2009-04 | PHASE4 |
| NCT00174239 | Pfizer | Parkinson Disease | 2004-07 | PHASE4 |
| NCT03735901 | University Hospital, Basel, Switzerland|Swiss National Science Foundation | Acute Stroke|Stroke Rehabilitation | 2019-06-14 | PHASE3 |
| NCT02601586 | University Hospital, Toulouse | Parkinson Disease | 2016-09 | PHASE2|PHASE3 |
| NCT07229651 | Tanta University | Parkinson Disease | 2025-11-10 | PHASE2|PHASE3 |
| NCT02346630 | Ross D. Zafonte, MD | Stroke | 2015-03 | PHASE4 |
| NCT00399477 | Teva Neuroscience, Inc. | Parkinson´s Disease | 2006-10 | PHASE4 |
| NCT00089622 | National Institute of Neurological Disorders and Stroke (NINDS) | Parkinson Disease | 2004-08-04 | PHASE2 |
| NCT00845000 | Merck Sharp & Dohme LLC|Oregon Health and Science University | Parkinson Disease | 2009-04-21 | PHASE1 |
| NCT06275633 | University Hospital Bispebjerg and Frederiksberg | Parkinson Disease|Medication|UPDRS|Motor Function|Cognitive Impairment|Depression|Impulsive|Levodopa | 2019-03-19 | NA |
| NCT01468012 | New York State Psychiatric Institute | Cocaine Dependence | 2014-07 | PHASE2|PHASE3 |
| NCT01937169 | Tel-Aviv Sourasky Medical Center | Restless Legs Syndrome | 2014-01 | NA |
| NCT07442591 | Shanghai WD Pharmaceutical Co., Ltd.|Shanghai Xuhui Central Hospital|BalGenSource Medical Technology Co. Ltd.|Shanghai Xihua Scientific Co., Ltd.|Shanghai BioGuider Medical Technology Co., Ltd. | Healhty | 2026-03-24 | PHASE1 |
| NCT00218075 | The University of Texas Health Science Center, Houston|National Institute on Drug Abuse (NIDA)|University of Texas | Cocaine Abuse|Cocaine-Related Disorders | 2000-03 | PHASE2 |
| NCT00086294 | National Institute of Neurological Disorders and Stroke (NINDS) | Parkinson´s Disease|Dyskinesias | 2004-06-25 | PHASE2 |
| NCT01351168 | Rush University Medical Center | Parkinson´s Disease | | PHASE2 |
| NCT07229664 | Tanta University | Parkinson Disease | 2025-11-10 | PHASE2|PHASE3 |
| NCT03119636 | Chinese Academy of Sciences|The First Affiliated Hospital of Zhengzhou University | Parkinson´s Disease | 2017-05 | PHASE1|PHASE2 |
| NCT00634556 | Washington University School of Medicine|National Institute of Mental Health (NIMH) | Tourette Syndrome | 2006-02 | PHASE1 |
| NCT00134966 | Novartis | Parkinson´s Disease | 2005-08 | PHASE3 |
| NCT04054960 | Western University, Canada | Parkinson Disease | 2019-09 | NA |
| NCT00692328 | Oregon Health and Science University|National Center for Complementary and Integrative Health (NCCIH) | Parkinson´s Disease | 2005-08 | NA |
| NCT04956939 | Rush University Medical Center | Parkinson Disease | 2018-07-17 | |
| NCT06115538 | Ankara Ataturk Sanatorium Training and Research Hospital | Parkinson Disease|Treatment Adherence | 2023-10-01 | PHASE4 |
| NCT00467597 | US Department of Veterans Affairs|Oregon Health and Science University | Dyskinesias|Movement Disorders|Parkinson Disease | 2006-04 | |
| NCT06365515 | University Hospital Tuebingen|German Research Foundation|Uppsala University | Hormonal Changes|Menstrual Cycle | 2024-05 | NA |
| NCT00406588 | Solvay Pharmaceuticals | Advanced Stage Parkinson´s Disease | 2007-03 | PHASE3 |
| NCT00306124 | University Hospital Muenster | Alzheimer´s Disease|Mild Cognitive Impairment|Healthy | 2006-01 | PHASE4 |
| NCT07246278 | Tanta University | Parkinson Disease | 2025-11-20 | PHASE1|PHASE2 |
| NCT00006077 | National Institute of Neurological Disorders and Stroke (NINDS) | Parkinson´s Disease | 2000-08 | PHASE2 |
| NCT00009048 | National Institute of Neurological Disorders and Stroke (NINDS) | Parkinson´s Disease | 2001-01 | PHASE2 |
| NCT00941265 | University Hospital, Geneva | Aphasia | 2007-02 | NA |
| NCT00153972 | Technische Universit?t Dresden|Pfizer | Parkinson´s Disease | 2005-02 | PHASE4 |
| NCT00108667 | National Institute of Neurological Disorders and Stroke (NINDS) | Parkinson Disease | 2005-04 | PHASE2 |
| NCT01484184 | Nordic Life Science Pipeline Inc.|United States Department of Defense | Spinal Cord Injury | 2013-07 | PHASE1|PHASE2 |
| NCT02560389 | University of Wisconsin, Madison | Stress Disorder, Post Traumatic | 2016-03 | PHASE4 |
| NCT02641054 | CleveXel Pharma | Idiopathic Parkinson Disease | 2016-02 | PHASE2 |
| NCT03000569 | Biogen | Parkinson Disease | 2016-11-30 | PHASE2 |
| NCT01327261 | University of Buenos Aires|Laboratorios Phoenix S.A.I.C.y F. | Healthy Volunteers | 2009-08 | PHASE4 |
| NCT02744391 | New York State Psychiatric Institute | Major Depressive Disorder|Dysthymia|Depression Not Otherwise Specified|Decreased Processing Speed|Decreased Gait Speed | 2016-08-24 | PHASE4 |
| NCT00076674 | National Institute of Neurological Disorders and Stroke (NINDS) | Dyskinesias|Parkinson Disease | 2004-01 | PHASE2 |
| NCT02554734 | Orion Corporation, Orion Pharma | Parkinson´s Disease | 2015-08 | PHASE1 |
| NCT02741947 | IRCCS San Raffaele Roma|Agenzia Italiana del Farmaco | Parkinson Disease | 2014-04 | PHASE4 |
| NCT01176435 | University of Minnesota | Albinism | 2010-09 | PHASE2 |
| NCT00040209 | National Institute of Neurological Disorders and Stroke (NINDS) | Parkinson Disease | 2002-06 | PHASE2 |
| NCT01227655 | Bial - Portela C S.A. | Parkinson´s Disease | 2011-03 | PHASE3 |
| NCT00102869 | University Hospital Muenster|German Federal Ministry of Education and Research | Cerebrovascular Accident|Aphasia | 2005-01 | PHASE4 |
| NCT06037590 | PureIMS B.V.|Cooperative Clinical Drug Research and Development AG (CCDRD AG) | Parkinson|Parkinson Disease|Parkinson´s Disease and Parkinsonism | 2023-09-25 | PHASE1 |
| NCT01044992 | University Hospital, Toulouse | Multisystemic Atrophy | 2002-05 | NA |
| NCT00660387 | AbbVie (prior sponsor, Abbott)|Quintiles, Inc. | Advanced Parkinson´s Disease | 2009-12 | PHASE3 |
| NCT00812760 | Medical University of Vienna | Retinal Diseases | 2001-10 | PHASE4 |
| NCT00505843 | Merck Sharp & Dohme LLC | Parkinson´s Disease | 2007-05 | PHASE1 |
| NCT05487300 | University of Utah | Parkinson Disease|Orthostatic Hypotension | 2022-05-11 | PHASE2|PHASE3 |
| NCT01577992 | University Hospital, Toulouse|Fondation de France | Pain Threshold|Multiple System Atrophy | 2011-12-01 | NA |
| NCT03205956 | Kevin J. Black, MD|Michael J. Fox Foundation for Parkinson´s Research | Parkinson´s Disease | 2017-10-19 | PHASE1 |
| NCT00103805 | University Hospital Muenster | Healthy | 2003-03 | PHASE4 |
| NCT05435729 | Sumitomo Pharma Co., Ltd. | Levodopa-induced Dyskinesia|Parkinson´s Disease | 2022-05-31 | PHASE1 |
| NCT01003002 | Oregon Health and Science University|Oregon Clinical and Translational Research Institute | Parkinson´s Disease | 2010-12 | |
| NCT03496870 | Neurocrine Biosciences | Parkinson Disease | 2018-02-08 | PHASE1 |
| NCT03055936 | Orion Corporation, Orion Pharma | Healthy Volunteers | 2017-02-21 | PHASE1 |